These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34773301)

  • 1. Real-world evidence on clinical outcomes of people with type 1 diabetes using open-source and commercial automated insulin dosing systems: A systematic review.
    Knoll C; Peacock S; Wäldchen M; Cooper D; Aulakh SK; Raile K; Hussain S; Braune K
    Diabet Med; 2022 May; 39(5):e14741. PubMed ID: 34773301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A real-world study of user characteristics, safety and efficacy of open-source closed-loop systems and Medtronic 670G.
    Jeyaventhan R; Gallen G; Choudhary P; Hussain S
    Diabetes Obes Metab; 2021 Aug; 23(8):1989-1994. PubMed ID: 33999488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended Use of an Open-Source Automated Insulin Delivery System in Children and Adults with Type 1 Diabetes: The 24-Week Continuation Phase Following the CREATE Randomized Controlled Trial.
    Burnside MJ; Lewis DM; Crocket HR; Meier RA; Williman JA; Sanders OJ; Jefferies CA; Faherty AM; Paul RG; Lever CS; Price SKJ; Frewen CM; Jones SD; Gunn TC; Lampey C; Wheeler BJ; de Bock MI
    Diabetes Technol Ther; 2023 Apr; 25(4):250-259. PubMed ID: 36763345
    [No Abstract]   [Full Text] [Related]  

  • 4. One-year real-world performance of the DBLG1 closed-loop system: Data from 3706 adult users with type 1 diabetes in Germany.
    Benhamou PY; Adenis A; Lebbad H; Tourki Y; Heredia MB; Gehr B; Franc S; Charpentier G
    Diabetes Obes Metab; 2023 Jun; 25(6):1607-1613. PubMed ID: 36751978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Automated insulin dosing systems: Advances after a century of insulin.
    Thabit H; Lal R; Leelarathna L
    Diabet Med; 2021 Dec; 38(12):e14695. PubMed ID: 34547133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical Guidance on Open Source and Commercial Automated Insulin Delivery Systems: A Guide for Healthcare Professionals Supporting People with Insulin-Requiring Diabetes.
    Lewis DM; Hussain S
    Diabetes Ther; 2022 Sep; 13(9):1683-1699. PubMed ID: 35913655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Why #WeAreNotWaiting-Motivations and Self-Reported Outcomes Among Users of Open-source Automated Insulin Delivery Systems: Multinational Survey.
    Braune K; Gajewska KA; Thieffry A; Lewis DM; Froment T; O'Donnell S; Speight J; Hendrieckx C; Schipp J; Skinner T; Langstrup H; Tappe A; Raile K; Cleal B
    J Med Internet Res; 2021 Jun; 23(6):e25409. PubMed ID: 34096874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Large-Scale Data Analysis for Glucose Variability Outcomes with Open-Source Automated Insulin Delivery Systems.
    Shahid A; Lewis DM
    Nutrients; 2022 May; 14(9):. PubMed ID: 35565875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do-It-Yourself (DIY) Artificial Pancreas Systems for Type 1 Diabetes: Perspectives of Two Adult Users, Parent of a User and Healthcare Professionals.
    Ahmed SH; Ewins DL; Bridges J; Timmis A; Payne N; Mooney C; MacGregor C
    Adv Ther; 2020 Sep; 37(9):3929-3941. PubMed ID: 32696329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Systematic Review of Commercial Hybrid Closed-Loop Automated Insulin Delivery Systems.
    Peacock S; Frizelle I; Hussain S
    Diabetes Ther; 2023 May; 14(5):839-855. PubMed ID: 37017916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do-It-Yourself Artificial Pancreas Systems: A Review of the Emerging Evidence and Insights for Healthcare Professionals.
    Jennings P; Hussain S
    J Diabetes Sci Technol; 2020 Sep; 14(5):868-877. PubMed ID: 31847570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6-12 years: a randomised, controlled, cross-over, non-inferiority trial.
    Kariyawasam D; Morin C; Casteels K; Le Tallec C; Sfez A; Godot C; Huneker E; Garrec N; Benhamou PY; Polak M; Charpentier G; Franc S; Beltrand J
    Lancet Digit Health; 2022 Mar; 4(3):e158-e168. PubMed ID: 35216750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice.
    Phillip M; Nimri R; Bergenstal RM; Barnard-Kelly K; Danne T; Hovorka R; Kovatchev BP; Messer LH; Parkin CG; Ambler-Osborn L; Amiel SA; Bally L; Beck RW; Biester S; Biester T; Blanchette JE; Bosi E; Boughton CK; Breton MD; Brown SA; Buckingham BA; Cai A; Carlson AL; Castle JR; Choudhary P; Close KL; Cobelli C; Criego AB; Davis E; de Beaufort C; de Bock MI; DeSalvo DJ; DeVries JH; Dovc K; Doyle FJ; Ekhlaspour L; Shvalb NF; Forlenza GP; Gallen G; Garg SK; Gershenoff DC; Gonder-Frederick LA; Haidar A; Hartnell S; Heinemann L; Heller S; Hirsch IB; Hood KK; Isaacs D; Klonoff DC; Kordonouri O; Kowalski A; Laffel L; Lawton J; Lal RA; Leelarathna L; Maahs DM; Murphy HR; Nørgaard K; O'Neal D; Oser S; Oser T; Renard E; Riddell MC; Rodbard D; Russell SJ; Schatz DA; Shah VN; Sherr JL; Simonson GD; Wadwa RP; Ward C; Weinzimer SA; Wilmot EG; Battelino T
    Endocr Rev; 2023 Mar; 44(2):254-280. PubMed ID: 36066457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Automated Insulin Delivery in Real Life (AID-IRL): Real-World User Perspectives on Commercial AID.
    Lewis D
    J Diabetes Sci Technol; 2022 Mar; 16(2):500-503. PubMed ID: 32935554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do-It-Yourself and Commercial Automated Insulin Delivery Systems in Type 1 Diabetes: An Uncertain Area for Canadian Health-care Providers.
    Morrison AE; Senior PA; Bubela T; Farnsworth K; Witteman HO; Lam A
    Can J Diabetes; 2022 Dec; 46(8):863-870. PubMed ID: 35945126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hybrid closed-loop therapy: Where are we in 2021?
    Leelarathna L; Choudhary P; Wilmot EG; Lumb A; Street T; Kar P; Ng SM
    Diabetes Obes Metab; 2021 Mar; 23(3):655-660. PubMed ID: 33269551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methods for insulin delivery and glucose monitoring in diabetes: summary of a comparative effectiveness review.
    Golden SH; Sapir T
    J Manag Care Pharm; 2012 Aug; 18(6 Suppl):S1-17. PubMed ID: 22984955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Real-World Prospective Study of the Safety and Effectiveness of the Loop Open Source Automated Insulin Delivery System.
    Lum JW; Bailey RJ; Barnes-Lomen V; Naranjo D; Hood KK; Lal RA; Arbiter B; Brown AS; DeSalvo DJ; Pettus J; Calhoun P; Beck RW
    Diabetes Technol Ther; 2021 May; 23(5):367-375. PubMed ID: 33226840
    [No Abstract]   [Full Text] [Related]  

  • 19. Real-world performance of the MiniMed™ 670G system in Europe.
    Da Silva J; Bosi E; Jendle J; Arrieta A; Castaneda J; Grossman B; Cordero TL; Shin J; Cohen O
    Diabetes Obes Metab; 2021 Aug; 23(8):1942-1949. PubMed ID: 33961340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: Findings from the first investigation with the Omnipod® 5 System.
    Polonsky WH; Hood KK; Levy CJ; MacLeish SA; Hirsch IB; Brown SA; Bode BW; Carlson AL; Shah VN; Weinstock RS; Bhargava A; Jones TC; Aleppo G; Mehta SN; Laffel LM; Forlenza GP; Sherr JL; Huyett LM; Vienneau TE; Ly TT;
    Diabetes Res Clin Pract; 2022 Aug; 190():109998. PubMed ID: 35853530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.